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The NF-κB pathway transcriptionally controls a large set of 
target genes that play important roles in cell survival, in-
flammation, and immune responses. While many studies 
showed anti-tumorigenic and pro-survival role of NF-κB in 
cancer cells, recent findings postulate that NF-κB partici-
pates in a senescence-associated cytokine response, the-
reby suggesting a tumor restraining role of NF-κB. In this 
review, we discuss implications of the NF-κB signaling 
pathway in cancer. Particularly, we emphasize the connec-
tion of NF-κB with cellular senescence as a response to 
chemotherapy, and furthermore, present examples how 
distinct oncogenic network contexts surrounding NF-κB 
produce fundamentally different treatment outcomes in 
aggressive B-cell lymphomas as an example.  
 
 
INTRODUCTION 
1 
The nuclear factor κB (NF-κB) is a transcription factor complex 
composed of homo- and heterodimers of five members of the 
Rel family including RelA (p65), RelB, c-Rel, NF-κB1 (p50/ 
p105), NF-κB2 (p52/p100). More than 25 years after it was first 
described as a nuclear protein binding to the kappa immunog-
lobulin light chain enhancer in B cells (Sen and Baltimore, 
1986), NF-κB is now known to control a complex signaling 
network via a long list of target genes in response to a variety of 
cellular stimuli. However, probably due to the pathway array 
surrounding NF-κB, ascribing common functions to NF-κB in 
general biological scenarios has been difficult. In tumor devel-
opment, NF-κB presents with Janus-like features that may 
have pro- and anti-tumorigenic implications. Similar opposing 
functionalities may apply to NF-κB’s role in cancer therapy, 
thereby making thorough analysis of NF-κB network a prere-
quisite for targeted treatment strategies related to NF-κB.  
 
NF-κB SIGNALING 
 
Of the five NF-κB family members in mammalian cells, p105 
and p100 are precursors, and, after post-translational modifica-
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tion and cleavage, become p50 and p52, respectively. They 
share a conserved Rel homology domain (RHD), which is re-
sponsible for binding to target DNA sequence, homo/hetero-
dimerization, and the interaction with the inhibitor protein IκB. 
With each other, NF-κB family members form homo- or hetero-
dimers, and in the absence of any stimulation (inactive state), 
also with IκB. Activation of the NF-κB signaling cascade can be 
divided into two pathways depending on how the active homo-
/heterodimers are produced. In the classical (or canonical) 
pathway, activation is achieved by releasing IκB from the inac-
tive complex via IκB kinase (IKK)-mediated phosphorylation 
followed by ubiquitin-mediated proteasomal degradation of IκB. 
The free NF-κB dimers (mainly p50/p65 and p50/c-Rel) trans-
locate to nucleus and activate target gene transcription. In the 
alternative (non-canonical) pathway, the activation of the NF-κB 
pathway is achieved by inducing post-translational processing 
of p100 to the p52 subunit. Here, IKK (mainly IKKα) phosphory-
lates p100, leading to polyubiquitination and proteasomal pro-
cessing to p52, which forms the transcriptionally active p52/ 
RelB dimer (Bonizzi and Karin, 2004; Hayden and Ghosh, 
2004).  
A wide range of stimuli, including inflammatory cytokines, 
bacterial and viral products, are known to activate the NF-κB 
pathway resulting in transcriptionally active NF-κB complexes 
as described above. The active complexes translocate into the 
nucleus and bind to discrete DNA sequences in promoters and 
enhancers of target genes to activate transcription. There are 
many NF-κB target genes, orchestrating a plethora of biological 
functions, including anti-apoptosis, cell adhesion, cellular stress 
responses, inflammation, and immunity (Hayden and Ghosh, 
2008).  
 
CONTROVERSIAL ROLES OF NF-κB IN CANCER  
DEVELOPMENT 
 
NF-κB activities are frequently deregulated in cancer, repre-
senting one of the most important signaling cascades in trans-
formed cells with mainly proto-oncogenic impact (Perkins, 2007). 
Constitutive activation of NF-κB has been observed in different 
kinds of cancer, including lymphoma, leukemia, breast, colon, 
liver, pancreas, prostate, and ovarian cancers. Moreover, acti-
vation of NF-κB has often been linked to recurrence, poor sur-
vival, tumor progression, aggressiveness, and chemoresis-
tance (Arkan and Greten, 2011; Basseres and Baldwin, 2006; 
Prasad et al., 2010). However, there are also studies that found 
NF-κB transcription factors or upstream activators rather to act 
as tumor suppressors. NF-κB controls the expression of a large 
set of target genes, including pro-survival and pro-inflammatory  
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transcripts, but the actual role of NF-κB as a tumor suppressor 
or rather a tumor promoter, as well as it’s potential interference 
with treatment outcome is controversial (Ben-Neriah and Karin, 
2011). 
 
Pro-oncogenic NF-κB 
Since NF-κB is normally involved in B-cell maturation and acti-
vation, deregulation of the NF-κB pathway is a prominent fea-
ture of hematological malignancies. Mutations in genes encod-
ing NF-κB subunits, IκB proteins, or upstream regulators were 
identified in a variety of hematological malignancies (Compag-
no et al., 2009; Franzoso et al., 1992; Neri et al., 1991). There 
are now a number of lymphoid malignancies known, where 
constitutive NF-κB has been implicated as an essential onco-
genic lesion. Mutations of multiple genes in receptor complexes 
(e.g. CD79-ITAM and MyD88), signaling complexes (e.g. 
TNFAIP3 [A20], CARD11-BCL10-MALT1 [CBM]), and the core 
signaling complexes (e.g. IKK, c-Rel) cause deregulation of NF-
κB pathway in human lymphomas (Ngo et al., 2011; Rosen-
wald et al., 2002; Sun et al., 2004; Zhou et al., 2004). A good 
example of NF-κB’s essential role in cancer development can 
be found in diffuse large B-cell lymphoma (DLBCL) which can 
be divided into at least two subtypes according to their gene-
expression profiling: the activated B-cell-like (ABC) subtype and 
the germinal-center B-cell-like (GCB) subtype. The main signa-
ture of the ABC subtype is the constitutive activation of the NF-
κB pathway, which is rarely hyperactivated in GCB-DLBCL. 
Activating mutations in CARD11 (which encodes Carma-1) 
have been detected in ABC DLBCL, generating constitutively 
active CARD11 that associates with the Bcl-10-MALT1 com-
plex (CBM complex; mediates NF-κB signaling between anti-
gen receptor and IKK) without antigenic stimulation, leading to 
persistent activation of NF-κB (Lenz et al., 2008a; Ngo et al., 
2006; Staudt, 2010). A20 is a negative regulator of the NF-κB 
pathway, as it prevents excessive activation of NF-κB in re-
sponse to a variety of external stimuli (Heyninck and Beyaert, 
2005; Wertz et al., 2004). It is frequently inactivated by truncat-
ing mutations and/or deletions in B-cell lymphomas, further 
adding to the theme that uncontrolled signaling of NF-κB is 
involved in the pathogenesis of B-cell malignancies. In multiple 
myeloma, another lymphoid neoplasia associated with NF-κB 
activation, no mutations in NF-κB or IκB encoding genes have 
been unveiled so far but extensive genetic analysis of primary 
tumors and multiple myeloma cell lines discovered a number of 
mutations in genes encoding upstream signaling molecules that 
lead to stabilization and accumulation of the NF-κB inducing 
kinase (NIK) in non-canonical pathway (Annunziata et al., 2007; 
Keats et al., 2007).  
Oncogenic mutations in NF-κB signal mediators appear to be 
rare in solid tumors. However, oncogenic signaling, for example 
from activated Ras, may enhance NF-κB activity in the ab-
sence of mutations. Moreover, inflammation-associated NF-κB-
driven cytokine production promotes carcinogenesis in a non 
cell- autonomous fashion (Ben and Karin, 2011; Staudt, 2010). 
Accordingly, mouse models demonstrated an oncogenic role 
for NF-κB in the development of lymphomas and solid tumors 
(Basseres et al., 2010; Calado et al., 2010; Yang et al., 2010). 
In addition, the number of tumors with activated nuclear NF-
κB is much larger than the fraction of malignancies with con-
firmed mutations in NF-κB-, IκB-, or typical upstream signal 
mediator-encoding genes. Such observations led to the pro-
posal that some of the NF-κB activation seen in cancer is due 
to crosstalk from other deregulated pathways that fuel into the 
NF-κB cascade or is the result of external stimuli such as expo-
sure to inflammatory cytokines in the tumor microenvironment. 
Production of the cytokines by immune cells that activate the 
NF-κB pathway in pre-malignant cells to induce genes that 
stimulate cell proliferation and survival is a major tumor-
promoting mechanism (Grivennikov et al., 2010). For example, 
TNFα and IL-1 secreted by the environmental cells were shown 
to act on premalignant cells where they activate NF-κB. NF-κB 
activation further induces expression of genes involved in 
blockade of apoptosis, promotion of proliferation and angioge-
nesis, mechanisms collectively contributing to malignant con-
version (Popivanova et al., 2008; Tu et al., 2008).  
 
Anti-oncogenic NF-κB 
Although NF-κB transcription factors have an oncogenic role in 
cancer development and confer drug resistance in cancer ther-
apy in some settings, other studies found NF-κB transcription 
factors or upstream activators rather to act as tumor suppres-
sors, thereby underscoring the complexity and potential context 
dependency of NF-κB network-mediated effector functions in 
both tumor development and therapy.  
Contributing to its anti-cancer property, NF-κB has been 
shown to mediate apoptosis in a variety of cell types (Ryan et 
al., 2000; Wang et al., 1998). For instance, RelA and c-Rel 
exert proapoptotic function in T cells, B cells, fibroblasts, neu-
ronal cells, and HeLa cells (Kaltschmidt et al., 2000; Kasibhatla 
et al., 1999; Martin et al., 2009; Schneider et al., 1999; Sheehy 
and Schlissel, 1999). There are also hints that NF-κB may 
modulate the apoptotic response depending on the develop-
mental stage of the immune cells. For example, overexpression 
of RelA caused a cell-cycle arrest that is followed by apoptosis 
in the pro-B cell line 220-8, whereas overexpression of RelA in 
the WEHI 231 immature B-cell line or in the mature B-cell line 
M12 did not induce apoptosis (Sheehy and Schlissel, 1999).  
Importantly, genetically defined mouse models supported the 
view that NF-κB transcription factors or upstream activators 
possess tumor suppressor functions. First evidence directly 
linking NF-κB to tumor suppression came from experiments 
using epidermal cells. Functional blockade of NF-κB in epider-
mal cells resulted in severe hyperplasia of the skin in transgenic 
mice expressing dominant negative IκBα mutant, which was 
reversible upon overexpression of active RelA and p50 sub-
units of NF-κB, suggesting a tumor-suppressive effect of NF-κB 
(Seitz et al., 1998). In a diethylnitrosamine-induced hepatocellu-
lar carcinoma (HCC) mouse model, hepatocyte-specific abla-
tion of IKKβ strongly enhanced the development of HCC (Mae-
da et al., 2005). In other studies, hepatocyte-specific ablation of 
IKKγ (NEMO) or TAK1 (TGF-β-activated kinase 1), both re-
quired for the activation of IKK and NF-κB, resulted in sponta-
neous liver damage, hepatocyte death, and interestingly, re-
lease of factors leading to liver fibrosis and development of 
HCC (Inokuchi et al., 2010; Luedde et al., 2007). In the Eμ-myc 
transgenic mouse lymphoma model, in which oncogene Myc is 
overexpressed and drives B-cell lymphoma, NF-κB2 loss acce-
lerated tumor development by impairing Myc’s apoptotic re-
sponse, adding an example for a tumor suppressive function of 
NF-κB via its non-canonical pathway (Keller et al., 2010). 
 
NF-κB IN CANCER TREATMENT RESPONSE:  
ANTI-APOPTOSIS 
 
Given the well-established overlap between failsafe barriers 
such as apoptosis and senescence in tumor development and 
therapy, the NF-κB pathway has also been linked to chemore-
sistance in cancer treatment. Activation of NF-κB occurs in 
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response to DNA damage, the mode by which most conven-
tional chemotherapeutic agents exert their anti-cancer activity. 
Among the NF-κB target genes activated by DNA damage are 
bcl-2 (Catz and Johnson, 2001), bcl-xL (Tamatani et al., 1999), 
COX-2 (Yamamoto et al., 1995), cyclin D1 (Guttridge et al., 
1999), survivin (Zhu et al., 2001), and XIAP (Stehlik et al., 1998), 
which are closely involved in anti-apoptotic, pro-survival func-
tions of NF-κB, thereby operating as candidate mediators of 
chemoresistance in a wide variety of tumor cells.  
Since the downstream targets of NF-κB are involved in apop-
tosis inhibition and may thereby block the action of many forms 
of chemotherapy (Baldwin, 2001), it may also contribute to the 
poor response of the ABC DLBCL to chemotherapy (Alizadeh 
et al., 2000; Lenz et al., 2008b; Rosenwald et al., 2002). This 
hypothesis is supported by several in vitro experiments. Intro-
duction of the NF-κB super repressor (a non-degradable mu-
tant of IκBα) resulted in rapid apoptosis and cell-cycle arrest, 
selectively in ABC-DLBCL cells (Davis et al., 2001). GCB-
DLBCL cells were not affected in the same condition, indicating 
that the constitutive NF-κB activity is specifically required for the 
survival and proliferation of ABC-DLBCL cells. Strictly speaking, 
such result shows only the lymphoma’s dependency on hyper-
active NF-κB, not the contribution of it to chemoresistance. 
However, it is non-disputable that NF-kB as the “Achilles’ heel” 
of ABC DLBCL is a good therapeutic target. Likewise, the IKKβ 
inhibitors PS-1145 and MLX105 were selectively toxic for ABC-
DLBCL cells but not for GCB DLBCL cells. Introduction of an 
estrogen-inducible RelA fusion protein into ABC-DLBCL res-
tored NF-κB activity even in the presence of IKK inhibition. The 
active form of RelA also stopped apoptosis induction by the 
kinase inhibitors PS-1145 and MLX105, demonstrating that the 
NF-κB inhibition is directly responsible for tumor cell death 
(Lam et al., 2005).  
 
NF-κB IN CANCER TREATMENT RESPONSE:  
CELLULAR SENESCENCE 
 
Premature cellular senescence is a terminal cell-cycle arrest 
that can be induced by oncogenic activation or chemotherapy, 
involving DNA damage response (DDR) signaling in both set-
Fig. 1. NF-κB signaling pathway and can-
cer related mutations. Only canonical
(classical) pathway is shown. Extracellular
stimuli transmitted though receptor com-
plexes activate IKK via phosphorylation.
Consequently, IKK phosphorylates IκB,
leading to its dissociation from inactive
NF-κB complex and ubiquitin-mediated
proteasomal degradation. Freed from IκB,
active NF-κB dimer translocates into the
nucleus and induces the transcription of
various target genes involved in multiple
cellular pathways. Cancer-relevant muta-
tions, indicated in orange boxes, can oc-
cur in all steps of NF-κB signaling cas-
cade.  
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Fig. 2. A model of how oncogenic network influences cancer treatment outcome. How two oncogenic moieties (NF-κB and bcl2) are con-
nected in a network at diagnosis - a linear pathway in which NF-κB drives bcl2 expression reminiscent of ABC DLBCL, or in independent pa-
rallel pathways reminiscent of GCB DLBCL - influences the cellular outcome and sensitivity to treatment using conventional chemotherapy 
and/or novel NF-κB inhibitor.  
 
 
 
tings (Kuilman et al., 2010; Schmitt, 2007). It has been demon-
strated that oncogene-induced senescence (OIS) imposes a 
critical barrier to tumor formation in vivo (Braig et al., 2005). 
Moreover, cellular senescence is increasingly recognized as a 
clinically relevant response to anti-cancer treatment, because it 
can be executed in response to therapeutic drugs and irradia-
tion (Chang et al., 1999). Indeed, therapy-induced senescence 
(TIS) is detectable in resected human tumor material after 
neoadjuvant chemotherapy (te Poele et al., 2002). Importantly, 
genetically defined mouse tumor models were instrumental to 
demonstrate that TIS indeed extends survival of the tumor-
bearing mice after chemotherapy (Schmitt et al., 2002). 
Interestingly, recent publications postulated that senescence-
associated and predominantly NF-κB-driven cytokines, collec-
tively termed “senescence-associated secretory phenotype 
(SASP)”, may reinforce the senescent cell-cycle arrest (Acosta 
et al., 2008; Coppe et al., 2008; Kuilmann et al., 2008; Rovillain 
et al., 2011). These - on first sight - counter-intuitive, double-
edged functions of NF-κB to promote both chemoresistance via 
anti-apoptosis and chemosensitivity via cellular senescence 
caught our attention to initiate an investigation to genetically 
determine the role of NF-κB in response to chemotherapy, with 
a special emphasis on TIS. By utilizing the Eμ-myc transgenic 
mouse lymphoma model, we first showed in vivo that TIS 
presents with and depends on active NF-κB signaling. To build 
a genetically modifiable model system reminiscent of the distin-
guishable NF-κB activities in ABC- vs. GCB-DLBCL, we classi-
fied primary Eμ-myc lymphomas by their NF-κB activity at di-
agnosis, i.e. prior to any therapy, and found “NF-κB high” (pro-
vocatively named “ABC-like”) lymphomas to be apoptosis-
defective and chemoresistant due to their strongly elevated 
expression levels of the NF-κB target bcl2. Notably, NF-κB high 
Myc-lymphomas failed to enter senescence in response to 
therapy, thereby further contributing to their drug insensitivity, 
although the underlying senescence-compromising mechanism 
is not entirely clear. Moreover, mice that relapsed upon chemo-
therapy had lymphomas with significantly higher NF-κB activity 
at diagnosis as compared to those achieving cure after a single 
application of cyclophosphamide, a common chemotherapeutic 
agent widely used in clinical oncology. Accordingly, we desig-
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nated “NF-κB low” mouse lymphomas “GCB-like”. Subsequent-
ly, we tested these “NF-κB low” lymphomas for their ability to 
enter TIS: after blocking apoptosis via retroviral introduction of 
bcl2, we observed more senescence in response to therapy if 
we genetically increased NF-κB levels. Parallel to mouse work, 
transcriptome and clinical data from DLBCL patients were also 
analyzed. Importantly - unlike ABC-DLBCL - almost half of the 
GCB-DLBCL are known to present with high Bcl2 levels that 
are independent of NF-κB activity, because they result from a 
t(14;18) translocation, which constitutively drives Bcl2 expres-
sion from an immunoglobulin heavy chain promoter (Huang et 
al., 2002; Iqbal et al., 2004), a scenario we recapitulated by 
retroviral, hence, NF-κB-independent Bcl2 expression in “GCB-
like” mouse lymphomas. Given the particularly TIS-prone condi-
tion in „GCB-like“ mouse lymphomas with high Bcl2 and high 
NF-κB levels, we re-applied these determinants to a 233-
DLBCL patient transcriptome data set with known subsequent 
clinical courses under standard immunochemotherapy. Indeed, 
patients with Bcl2-high and NF-κB-high GCB-DLBCL at diag-
nosis were identified as a clinically relevant subcohort that 
achieved a significantly longer (P < 0.005) progression-free 
survival than patients with Bcl2-high GCB-DLBCL but low NF-
κB activity. Hence, functional investigations in mice identified an 
array of novel stratifiers of response that unveiled the clinically 
unexpected finding of a patient subgroup with a particularly 
good prognosis despite high-level NF-κB activity. All together, 
these data underscore the opposing roles NF-κB plays in can-
cer treatment, dependent on the cellular context, which ac-
counts for fundamentally different clinical outcomes even in the 
same cancer entity.  
 
NF-κB IN CANCER TREATMENT RESPONSE:  
ONCOGENIC NETWORKS 
 
The data described above highlight how oncogenic networks 
and interdependencies, wired up during tumor development, 
may regulate the actual functions and even opposing roles of 
NF-κB in subsequent responses to therapy. NF-κB and Bcl2 
are generally considered as indicators of aggressive tumor 
biology and poor outcome, but our mechanistic analyses in a 
genetically tractable mouse lymphoma model unveiled a setting 
in which these moieties contribute to superior outcome. Our 
approach demonstrates that functional understanding of onco-
genic networks - and NF-κB/Bcl2 forms the most simple model 
of such a "two-factor network" with a linear connection in one 
(ABC-type), but an independent role of both factors in the other 
setting (GCB-type) - is required to properly utilize molecular 
lesions as biomarkers or even therapeutic targets (Fig. 2). 
 
NF-κB IN CANCER TREATMENT RESPONSE: SASP 
AND TUMOR MICTROENVIRONMENT 
 
The SASP is composed of pro-inflammatory cytokines such as 
IL-1α, IL-1β, IL-6, IL-8, bFGF, TGF-β (in some settings), GM-
CSF, as well as inflammation-related chemokines such as 
CXCL-1/-2/-3/-5/-7, MIP-1α, or MCP-1 (a.k.a. CCL2). It also 
contains factors with, at least in some contexts, anti-proliferative 
activity such as IGFBPs or PAI-1, as well as factors like the 
MMPs that remodel the extracellular matrix (Acosta et al., 2008; 
Kortlever et al., 2006; Kuilman and Peeper, 2009). Moreover, in 
an extend view on the SASP program as a senescence-
associated pro-inflammatory signaling array, this phenotype is 
not restricted to secreted factors, but also includes membrane-
bound cell surface molecules serving as ligands and receptors, 
for instance TNF receptors, CXCR2 or the IL-6R, thereby creat-
ing potential autocrine loops (e.g. CXCL-1/-5/-7 or IL-8 with 
CXCR2) or even, as reported, intra-cellular short cuts (e.g. IL-6 
and the IL-6R), and self-amplifying cascades (e.g. NF-κB sig-
naling via TNF-R).  
Therefore, the expression of surface-presented receptors 
and ligands and the secretion of a plethora of factors by senes-
cent cancer cells may have complex, growth-inhibitory or -
promoting effects on adjacent tumor and surrounding bystander 
cells. In particular, factors secreted by senescent cells can also 
act on macrophages, neutrophils, and NK cells, thereby pro-
moting immune responses that, on one hand, may ultimately 
lead to the clearance of senescent tumor cells (Xue et al., 
2007), but, on the other hand, might also create a microenvi-
ronment that fosters tumor progression (Coppé et al., 2010). 
Given our own observation that macrophage-derived TGFb 
evokes lymphoma cell senescence in a non-cell-autonomous 
fashion (Reimann et al., 2010), SASP-activated macrophages 
are likely to contribute to TIS in vivo, or, in turn, NF-κB inactiva-
tion in lymphoma cells might result in an inability to launch TIS 
because of the disrupted SASP/macrophage link. Thus, the 
outcome of anticancer therapy is not only determined by a 
quantitative effect on cancer cells forced to irreversibly exit the 
cell cycle but may also depend on novel capabilities acquired 
by senescent cells that can impact on their malignant and non-
malignant neighbors in different ways. With further elucidation 
of these complex interdependencies that regulate tumor cell 
survival, senescence, and immune clearance, we expect non-
genotoxic senescence-inducing agents to become a very prom-
ising perspective to be further exploited in cancer treatment. 
 
NR-κB AS CANCER TREATMENT TARGET: A CAUTIOUS 
NOTE 
 
Chemotherapy is still the most important treatment method for 
many types of cancer. The possible outcomes of chemothera-
peutic treatments reach from necrosis, apoptosis, mitotic catas-
trophe, and autophagy to cellular senescence. Most of the 
chemotherapeutic agents used in the clinic are assumed to 
exert their anti-tumor effect through the induction of apoptosis. 
Accordingly, cancer cells with apoptotic defects would exhibit 
chemoresistance. As an example, ABC-subtype DLBCL pre-
sent with an inferior prognosis after chemotherapy, and are 
characterized by constitutive activation of the NF-κB pathway, 
which appears to confer treatment resistance via an apoptotic 
block. In contrast, another subtype of DLBCL with lower NF-κB 
activity (i.e. the GCB subtype) is associated with a much better 
response to chemotherapy. In vitro analyses demonstrated that 
inhibition of NF-κB can sensitize ABC- but not GCB-DLBCL to 
apoptotic cell death; therefore, the hyperactive NF-κB pathway 
is central to the pathogenesis of ABC DLBCL and serves as a 
potential treatment target selectively in this subgroup. Many 
trials using specific NF-κB inhibitors or more broad range of 
proteasome inhibitors, which suppress NF-κB activation by 
preventing the degradation of IκB, are ongoing (Lim et al., 
2012; clinicaltrialsfeeds.org). However, such treatment should 
be applied with caution. Because, in addition to the concerns of 
acquired resistance and impaired immunological functions of 
patients after repeated treatments, it may not be even clear 
who can benefit from NF-κB inhibition, considering the signifi-
cant role NF-κB plays in cellular senescence. Coming back to 
the example of DLBCL, cross-species analysis of mouse lym-
phoma model and patient data revealed a patient cohort of 
GCB DLBCL, which seems not to be affected by NF-κB activa-
NF-κB in Cellular Senescence and Cancer Treatment 
Hua Jing & Soyoung Lee 
 
 
194  Mol. Cells http://molcells.org 
 
 
tion at first sight, with high Bcl2 level, actually benefit from high 
NF-κB activity (Fig. 2). Here, cellular senescence induced by 
chemotherapy and mediated by NF-κB is a key factor for the 
better treatment outcome. This contrasting impact of NF-κB in 
the same cancer entity should alert us to the consequence of 
(simply) adding NF-κB antagonists in cancer treatment regi-
mens. Even more, the SASP factors, many of which controlled 
by NF-κB, may also contribute to treatment outcome not only 
by affecting tumor cells themselves, but also by modifying the 
tumor microenvironment in non-cell-autonomous ways. Consi-
dering that the simple oncogenic network of only two factors 
(NF-κB and bcl2) already create multiple scenarios for possible 
treatment responses (Fig. 2), one can easily imagine how com-
plicated it can be to predict cancer treatment outcomes in indi-
viduals with still unknown factors, emphasizing the importance 
of understanding the network of genes for the development of 
personalized medicine designed for individual patient. 
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